Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | RARA | P10276 | 3/20 | 0.40 |
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | RARG | P13631 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605552 | 1.00 | MAP3K14 (0.49) | MAP3K14AKR1B1RARARARBRARG | |
| SCHEMBL5399703 | 1.00 | MAP3K14 (0.49) | MAP3K14AKR1B1RARARARBRARG | |
| SCHEMBL11367364 | 0.87 | MAP3K14 (0.47) | MAP3K14AKR1B1RARARARBRARG | |
| SCHEMBL6578141 | 0.82 | AKR1B1 (0.44) | MAP3K14AKR1B1RARARARBRARG | |
| SCHEMBL6578015 | 0.82 | AKR1B1 (0.64) | AKR1B1 | |
| SCHEMBL6761742 | 0.78 | MAP3K14 (0.43) | MAP3K14AKR1B1RARARARBRARG | |
| SCHEMBL6580916 | 0.78 | RAB9A (0.43) | AKR1B1RARARARBRARGNPC1 | |
| SCHEMBL6606788 | 0.78 | MAP3K14 (0.43) | MAP3K14AKR1B1RARARARBRARG | |
| SCHEMBL27999909 | 0.78 | AKR1B1 (0.41) | MAP3K14AKR1B1 | |
| SCHEMBL6981620 | 0.77 | MAP3K14 (0.42) | MAP3K14AKR1B1RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716834-B2 | ANTICOAGULANTS. | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| EP-1283837-B1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2003-11-27 | — | — | US | disclosed |
| EP-1283837-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087879-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | SERPINC1, F2, TFPI | MAP3K14 2865/4885AKR1B1 1031/4885RARA 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.